NSB — Neuroscientific Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$21.82m
- AU$17.28m
- AU$0.63m
Brief: Neuroscientific Biopharmaceuticals Seeks Trading Halt
Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results
Brief: Neuroscientific Biopharmaceuticals Requests Trading Halt
Brief: Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO
Australia's NeuroScientific Biopharmaceuticals soars on buying biotech co
Brief: Neuroscientific Biopharmaceuticals To Acquire Stemsmart Patented Stem Cell Technology
Brief: Neuroscientific Biopharmaceuticals Seeks Trading Halt
Brief: Neuroscientific Biopharmaceuticals Says Appointed Chris Ntoumenopoulos As Non-Executive Chair
Brief: Neuroscientific Biopharmaceuticals Says Resignation Of CEO Stephen Carter
Brief: Neuroscientific Biopharmaceuticals Says Stephen Carter Appointed CEO
Brief: Neuroscientific Biopharmaceuticals Says Paul Rennie Appointed As Interim CEO
Australia's NeuroScientific Biopharma surges on stroke treatment drug hopes
Brief: Neuroscientific Biopharmaceuticals Announces Resignation Of CEO
NeuroScientific Biopharmaceuticals hits record low on clinical trial rejection
Brief: Neuroscientific Biopharmaceuticals Says Net After-Tax Loss For Year A$10.5 Million
Australia's NeuroScientific jumps on positive prelim drug trial data
Australia's NeuroScientific Biopharmaceuticals rises on ethics approval for drug trial
Australia Stock Exchange release from NEUROSCIENTIFIC : Company Presentation
Australia Stock Exchange release from NEUROSCIENTIFIC : NSB presenting at Broker Briefing Investor Webinar